Peptides Merchant Account

Yes. Research peptides are legal to sell in the United States when they are marketed strictly for research use only, and merchant accounts are available through acquiring banks that knowingly support the vertical. What you cannot do is process on a mainstream aggregator like Stripe, PayPal, or Square, because their acceptable-use policies exclude the category — which is why sellers who start there are usually frozen within weeks.

Most declines are avoidable and come down to presentation rather than the business itself. The common causes are human-consumption or dosing language on product pages, missing research-use-only disclaimers, a mismatch between the legal entity name, tax ID, and bank account, or applying through a broker who does not understand the vertical and submits the file incorrectly.

Yes. Alongside the US program we place research peptide accounts for Canadian and international businesses, and the application is built for that from the start. An EIN and a Social Security number are US federal identifiers, so a foreign entity is never asked for them — a Canadian applicant provides a Business Number, and an international applicant provides the registration and tax ID issued in its own country. The underwriting standard is the same everywhere: a properly registered entity, research-use-only labeling, and a bank account in the matching legal name.

Peptides Payments is the research-peptide program of Spectrum Payment Solutions, a high-risk payment specialist with over 20 years in the industry and more than $5 billion processed. Spectrum places accounts across a range of restricted verticals; this site covers the peptide program specifically, which is why underwriting here is handled by people who review these storefronts every day rather than by a generalist support queue.

Most complete applications get a same-day underwriting decision, and live processing typically follows within a few business days once integration is done. Incomplete paperwork is the single largest source of delay, which is why the storefront and document review happens before submission rather than after a decline.

High-risk pricing is quoted per business rather than from a rate card, because it depends on your monthly volume, average ticket, chargeback history, and product mix. Expect rates above standard retail processing, since the acquiring bank is pricing genuine risk. You should always receive the full fee schedule in writing before you sign anything.

Not for every peptide program, but certification meaningfully strengthens an application and is required by some banks and advertising platforms. We will tell you honestly whether it is worth pursuing for your specific catalog rather than pushing you toward a cost you may not need.

Sometimes. A reserve is a percentage of volume the bank holds temporarily against future disputes, and it is common for newer high-risk accounts or those without processing history. Reserves are frequently reduced or released once the account demonstrates a clean chargeback record, and the terms should be disclosed up front.

Yes, and for peptide sellers it is often the smartest structure. Running more than one acquiring relationship means a pause on one account does not stop revenue on the other. Redundancy is the difference between an inconvenience and a shutdown.

It is still worth applying. A prior termination or a MATCH listing narrows the options and affects pricing, but it is not automatically disqualifying — the reason code and how you have operated since matter a great deal. Be upfront about it, because underwriting will find it and undisclosed history is far more damaging than the history itself.